ROSE PHARMA
News & Announcements
The latest company news, research updates, and press releases.
Scientific Review Highlights ROSE-010’s Clinical Evidence in Acute IBS Pain
A narrative review published in the Journal of Clinical Medicine discusses ROSE‑010 as a distinct example of GLP‑1 receptor modulation being investigated for acute irritable bowel syndrome (IBS) pain relief. The review examines previously published ROSE‑010 clinical research, highlighting evidence of acute pain relief and stronger signals in patients with constipation-predominant IBS (IBS-C) and mixed-type […]
Rose Pharma-Sponsored Patient Preference Research Accepted for Presentation at ObesityWeek® 2026
PRESS RELEASE Research examines patient preferences for flexibility and control in obesity treatment VIRGINIA BEACH, Va. — September 9, 2026. Rose Pharma Inc. is pleased to announce that its sponsored abstract, led by Angela Fitch, MD, FACP, MFOMA, Dipl. ABOM, entitled “Why Adults With Obesity Decline GLP-1 Therapy: Preference for Limited Medication Exposure,” has been […]
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
PRESS RELEASE Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif., September 9, 2026 (Globe Newswire) – MannKind Corporation (Nasdaq: […]
Presenting Phase 2a Results of ROSE-010 at Obesity Week 2025
PRESS RELEASE Rose Pharma Inc. to Present Positive Phase 2a Results of ROSE-010 in Obesity at ObesityWeek® 2025 Poster presentation will highlight blinded, placebo-controlled data on mealtime food intake, caloric reduction, satiety, GI tolerability, safety, and weight loss VIRGINIA BEACH, Va. — October 24, 2025 — Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, […]